Polaryx Therapeutics, Inc.
$5.7
▼
-6.05%
2026-04-21 08:53:00
polaryx.com
NCM: PLYX
Explore Polaryx Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$289.74 M
Current Price
$5.7
52W High / Low
$48.91 / $2.2
Stock P/E
—
Book Value
$0.1
Dividend Yield
—
ROCE
-171.33%
ROE
-1.94%
Face Value
—
EPS
$-0.19
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
2
Beta
—
Debt / Equity
—
Current Ratio
8.54
Quick Ratio
8.55
Forward P/E
—
Price / Sales
—
Enterprise Value
$263.77 M
EV / EBITDA
—
EV / Revenue
—
Rating
None
Target Price
$10
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | MiNK Therapeutics, Inc. | $12.82 | — | $63.66 M | — | 859.68% | 57.3% | $76 / $6.34 | $-3.02 |
| 2. | Aligos Therapeutics, Inc. | $6.51 | — | $41.33 M | — | -130.74% | -1.97% | $13.69 / $4.2 | $8.67 |
| 3. | Caribou Biosciences, Inc. | $2.29 | — | $212.6 M | — | -90.82% | -78.97% | $3.54 / $0.71 | $1.28 |
| 4. | Telomir Pharmaceuticals, Inc. | $1.48 | — | $49.85 M | — | -178.22% | -3.18% | $3.1 / $1.05 | $0.17 |
| 5. | Tiziana Life Sciences Ltd | $1.21 | — | $143.81 M | — | -401.27% | -2.32% | $2.6 / $0.87 | $0.08 |
| 6. | Denali Therapeutics Inc. | $20.54 | — | $3.26 B | — | -53.07% | -45.69% | $23.77 / $12.31 | $6.49 |
| 7. | Evommune, Inc. | $27.97 | — | $988.7 M | — | -39.16% | -54.42% | $33.2 / $13.88 | $6.52 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -0.91 M | -0.97 M | -0.88 M | -5.05 M | -0.72 M | — |
| Net Profit | -1.5 M | -1.43 M | -1.01 M | -5.05 M | -0.72 M | — |
| EPS in Rs | -0.03 | -0.03 | -0.02 | -0.11 | -0.02 | -0.02 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Sales | 0 M | 0 M | 0 M |
| Operating Profit | -7.82 M | -4.35 M | -3.78 M |
| Net Profit | -8.98 M | -30.36 M | -3.78 M |
| EPS in Rs | -0.19 | -0.64 | -0.08 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Total Assets | 5.17 M | 5 M | 2.31 M |
| Total Liabilities | 0.6 M | 0.29 M | 1.04 M |
| Equity | 4.57 M | 4.71 M | 1.28 M |
| Current Assets | 5.17 M | 5 M | 2.31 M |
| Current Liabilities | 0.6 M | 0.29 M | 1.04 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Operating CF | -3.94 M | -2.57 M | -0.17 M |
| Investing CF | — | — | — |
| Financing CF | 4.47 M | 7.19 M | 0.13 M |
| Free CF | -3.94 M | -2.57 M | -0.17 M |
| Capex | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue Growth % | — | — | — |
| Earnings Growth % | 70.4% | -703.28% | — |
| Profit Margin % | — | — | — |
| Operating Margin % | — | — | — |
| Gross Margin % | — | — | — |
| EBITDA Margin % | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.